Background {#Sec1}
==========

The mushroom known as the deadly webcap or *Cortinarius rubellus* (synonymous with *Cortinarius speciosissimus*) is occasionally mistaken for eatable chanterelles \[[@CR1]--[@CR5]\], Fig. [1](#Fig1){ref-type="fig"}. The habitats are unevenly distributed in Europe and North America and reports of poisoning episodes have been made from forestry areas throughout these regions. One to three of the deadly webcaps is considered enough to cause severe renal failure. There are usually no acute symptoms and the patient will seek medical advice 3 days to a week later with the symptomatology of uraemia caused by an acute kidney injury. The main symptoms of the uraemia at this stage are nausea and fatigue. Edema is less common due to an initial polyuric phase. This is in turn due to the tubulo-interstitial nephritis caused by damage to the tubular cells. In case of more severe poisoning, the patient becomes anuric after around 1 week \[[@CR4]\].Fig. 1Specimens of the deadly webcap or *Cortinarius rubellus* (synonymous with *Cortinarius speciosissimus*), younger and older mushrooms with slightly different appearance. Picture by Hans Marklund

The deadly webcap contains a highly selective nephrotoxin, orellanine, first described by Grzymala \[[@CR6]\]. Orellanine (or \[2, 2′-bipyridine\]-3, 3′,4, 4′-tetrol-1, 1′-dioxide) is present in the mushroom in its basic form as a di-glycoside \[[@CR7], [@CR8]\]. The mechanism of action is that orellanine generates oxygen radicals \[[@CR9]--[@CR11]\] and simultaneously shuts down the oxidative defence, by down-regulating most anti-oxidative enzymes \[[@CR9]\]. In rodents, the highly kidney-specific nature of orellanine has been verified. Thus, no acute symptoms have been observed at doses 1--2 orders of magnitude higher than the dose required to elicit acute renal failure \[[@CR12], [@CR13]\].

There are several case reports of the acute intoxication \[[@CR1], [@CR2], [@CR14]--[@CR18]\]. Due to the lag-phase between intake and symptoms, there are no signs of toxins in blood \[[@CR19]\]. Suggested therapies during the years have been hemodialysis, hemoperfusion, corticosteroids and anti-oxidant therapies with highly varying and inconclusive results \[[@CR4], [@CR20], [@CR21]\]. Regarding long-term effects of the intoxication, there are only a few reports following transplantation \[[@CR17], [@CR22]\]. There are no long-term follow up on patients after the initial acute kidney injury phase. Therefore, we tried to identify all cases of deadly webcap intoxication during the last three decades in the most affected (South-Western) region of Sweden and compared their outcome with a case-control group of patients. Our hypothesis was that the poison might have long-term effects or increase patient morbidity and mortality. Hence, a long time follow up of a patient cohort would be of interest.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

We included all patients accidentally poisoned by intake of the mushroom deadly webcap (or *Cortinarius rubellus*, also known as *Cortinarius speciosissimus*) admitted to any of the hospitals in the Western part of Sweden during the period of January 1979 to December 2012. The total number of patients was 39. In this report, 28 patients were included based on informed consent and available medical records, see Table [1](#Tab1){ref-type="table"} for demographic data.Table 1Demographic data of the Cortinarius intoxicated patient cohortCont on dialysisGFRGFR YearAge at intoxAdmission YearCreaAlatAlpBilUreaAsatCancerNo.Biopsy\
(Y/N)† Year1st trpl Year2nd trpl YearInitial dialysisCKD5BPHbAlbInital peak values first w. after intoxicationafter intox1^a^NNNN471979130/70116398890,223,659N2^a^NNNN241979140/80149P 714000,192,990,333N1980YNY352011441979185/1001241550*0,336*37*0,3*Y^b^4N1986YNY552012601985170/11095P 715420,544,17,5230,52Y^c^5YYNN261985120/80861270*0,337*17*0,3*N6^a^N19871999YNY3820042119857Y19882003YNY1072009141987130/80101180024N8N2012NNN401987130/80144P 671260,72,2110,479^a^NYYY26199010NYYY16199011N19922004YNY391991130/701233213330,4737,4450,23N12N1992YNY411991130/801193210740,193,37,9340,17N13N1992YNY211991135/801254514580,142,77,5420,24Y^d^14N19991983YNY411979160/901434116304615N2000YYY681984180/95125P 72970*0,3370,3*16N2000YNY28200328199917N2001YNY52200227199918N2002YNY4420123620011100*0,3370,3*N19N1995YYY40601984180/100111P 699700,262,214100,3120Y2007YYY46199921N2013YNY482007129/7110520,281,46,427,60,3N22N2009YNY402009522007174/97N23^a^NNNN252010160/1041152430,451,1624Y2012YNY112012572010125/871273728090,1217,9N25^a^NYYY612011145/80982313003526NYYY392011150/801373010810,220,6250,47N27^a^NNNN482011140/80152347100,61,36,925,20,72N28^a^YNNN552012125/80152334730,511,58,2NPatient data.^a^ = no matched control available, F: female, M: male, TRPL: kidney transplantation, CKD: Chronic kidney disease, GFR: measured glomerular filtration rate, BP: blood pressure, Hb: hemoglobin value in g/L, Alb: serum albumin (in some cases protein was measured: P) g/L, Crea: creatinine in umol/L, Alat / Asat / ALP, values measured in μCat/L bilirubin (bil) measured in μmol/L. Liver values reported as normal was estimated *(shown in italics).*Y^b^: Oral cancer, Y^c^: Skin cancer, Y^d^: Hodgkins Lymphoma

Case control population {#Sec4}
-----------------------

For each patient included in the study population that developed CKD5 (chronic kidney disease stage 5), we randomly included another patient as case control from the dialysis unit and another from the transplantation centre at Sahlgrenska University Hospital. Patients with diabetes or other systemic disease were excluded. The case controls were matched in age, sex, comorbidity and the year of the initiation of dialysis or transplantation. Such case control subjects could be found for all study patients in the dialysis group. However, three case controls are missing during certain years for the transplantation group due to large age differences. Most of the case control patients included had interstitial nephritis (75%), glomerulonephritis, or polycystic kidney disease, see Table [3](#Tab3){ref-type="table"} for demographic data.

Kidney morphology {#Sec5}
-----------------

Kidney biopsies were taken using gauge 16 needles, fixed in buffered paraformaldehyde, embedded in paraffin, sectioned and stained with standard dyes (haematoxylin-eosin, trichrome, silver and periodic acid-Schiff) and evaluated by a renal pathologist.

Statistical analysis {#Sec6}
--------------------

*Results are presented as mean ± SEM (standard error of the mean). Differences between groups were calculated using the Gehan-Breslow-Wilcoxon test.*

Results {#Sec7}
=======

Study population {#Sec8}
----------------

Of the 39 patients identified, we were able to include 28 patients in the study. This was mainly due to difficulties to be able to get in contact and obtain an informed consent form from all patients.

Of the 28 patients, 22 required dialysis initially, and 6 did not, Table [1](#Tab1){ref-type="table"}. After 1 month, 21 patients had CKD5 requiring dialysis or transplantation and 7 patients had CKD stage 3. Thus, there was a 4.5% chance for a patient initially requiring dialysis to regain renal function during the first month after the intoxication (1/22). Of the 7 patients that were dialysis-free 1 month after the intoxication, all regained most of their renal function within the first year reaching CKD stage 1 or 2.

For the total study population of 28 patients, the average time of follow-up was 16.9 ± 2.1 years (minimum 1.24 and maximum 34.3 years). 23 patients were alive at the time of follow up, but five had died at ages of 67.0 ± 5.1 years. Over the long observation period, three patients with end stage renal disease (ESRD) and hemodialysis died at the age of 70 ± 9 years after 11.9 ± 2.5 years on dialysis.

One patient who never required dialysis died 24 years after the intoxication at the age of 65. Another patient died 19.1 years after the intoxication and 16 years after a successful kidney transplant at the age of 61. Fourteen patients were transplanted and of these three had a second kidney graft 12--15 years after the first one. The average age at the time of the accidental intake of poisonous mushrooms was 40 ± 3 years (*n* = 28), and 64% of patients were male. In the study group, 3 of the 16 transplanted patients developed cancer in the form of lymphoma, oral or skin cancer. Information of the specific cancer diagnosis was not available for the case control group.

### Acute effects {#Sec9}

The serum creatinine of the patients requiring dialysis peaked at 1 329 ± 133 μmol/l (*n* = 15) and serum urea reached 31 ± 3.5 mmol/l (*n* = 11). The peak creatinine and urea values were markedly lower in patients that did not require dialysis, Table [1](#Tab1){ref-type="table"}. Laboratory tests did not show signs of damage in any other organ apart from the kidney. Thus, the aspartate amino transferase (ASAT), alanine amino transferase (ALAT), alkaline phosphatase (ALP) and bilirubin values were all within their normal limits in the patients analyzed; 0.35 ± 0,04 μCat/l, 0.34 ± 0.04 μCat/l, 2.38 ± 0.04 μCat/l, and 7.59 ± 0.5 μmol/l respectively (n~ALAT~ = 14, n~ASAT,\ ALP,\ bilirubin~ = 18).

### Patients with non-dialysis dependent kidney injury {#Sec10}

Six of the patients that were orellanine intoxicated developed a less severe kidney injury and never required dialysis. On average their serum creatinine peaked at 474 ± 117 μmol/l (*n* = 3) during the first week. Initially, two patients were treated with three sessions each of hemoperfusion with charcoal, which in 1979 was suggested as therapy. One patient initially required dialysis and had a serum creatinine of 1270 μmol/l, but regained part of her renal function within the first month, and had a glomerular filtration rate of 87 ml/min 1 year later determined by ^51^Cr-EDTA clearance. The 7 patients who did not develop CKD5 were followed over a time-period of 18.3 ± 5.8 years, range 1.2--34.3 years.

### Patients with dialysis-dependent chronic kidney disease stage 5 {#Sec11}

One month after the intoxication, 21 of 22 patients still required dialysis. 14 of them were transplanted, 6 received a kidney graft from a living donor and 8 from a dead donor. Before transplantation, the patients had been on dialysis for 19 ± 4 months (range 7--64 months). Three renal grafts lost their function after 11, 12 and 15 years and a second kidney transplantation was performed. Those patients now have been living with their 2nd grafts for 10, 11 and 15 years, Table [1](#Tab1){ref-type="table"}.

### Kidney morphology {#Sec12}

Kidney biopsies were obtained from 5/28 patients. The biopsy material from one patient could not be retrieved and thus material was available from 4 patients. According to clinical data biopsies were obtained 10--21 days after fungal ingestion. All biopsies showed a similar pattern dominated by acute tubular necrosis (ATN), Fig. [2](#Fig2){ref-type="fig"}. Two patients (no 5 and 28) showed less severe damage with focal involvement, while the other two biopsies (no 20 and 24) showed a diffuse involvement with generalized inflammation and tubular damage. These biopsies also showed tubular dilatation, tubular cellular atrophy and degeneration, Table [2](#Tab2){ref-type="table"}. All biopsies contained some apoptotic bodies, interstitial edema and focal inflammation but no eosinophilia. Fibrosis was not a prominent finding.Fig. 2Light microscopy from a Cortinarius intoxicated patient showing proximal tubular damage (arrows) in some tubules. There are focal apoptotic bodies (arrowheads), denudation and tubular dilatation (★). Haematoxylin-eosin stain Table 2Renal morphology of biopsies from patients with Cortinarius poisoningPatient No.Time after ingestionTubular damage: Necrosis, apoptosis, degeneration, dilatation, involvementEdemaInflammationFibrosis52v0 + 0 0focalminimalminimalminimal7\-\-\-\-\-\-\--203v+ + + +diffusesevereprominentminimal24\>10d0 + + +diffuseprominentslightslight2810d0 + 0 0focalfocalminimalminimal

Case control population {#Sec13}
-----------------------

The case control patients were age and sex matched, and they started dialysis or were transplanted in the same year as the patients in the study population, Table [3](#Tab3){ref-type="table"}. No acceptable case control could be found for three of the 16 transplanted study patients since the candidates were either too old or had systemic disease. The distribution of kidney disease within the population is displayed in Table [3](#Tab3){ref-type="table"}. In total, 20 patients were matched, 7 of the patients were on dialysis and the remaining 13 patients were transplanted, one of them twice. Of the 20 patients, 6 died at a mean age of 67.5 ± 4.7 years after 16.9 ± 6.6 years on dialysis (*n* = 3, at a mean age of 68 years) and 10.3 ± 2.2 years after transplantation (*n* = 3, at a mean age of 66 year), Fig. [3](#Fig3){ref-type="fig"}. In the case control population, one patient died of cancer and three other patients developed tumours during the observation period.Table 3The table describes the demographic data available for the matched control cohort^a^second transplant in 2003A. Matched control patients who had hemodialysisNo\#:Born yearTransplant 1DiagnosisFollow up MFollow up YDeath YCoDCancer119351980PCK356302010PeritonitisY219251986Amylioidosis9581994UnknownY319652002Crescentic GN14112N419532012IgAN202N519582012PCK222N619552009PCK595N719421983Pyelonephritis36831819721988^a^PCK30726N919702000Interstitial Nephritis156131019732001IgAN194161119521992IgAN157132005EpilepsyN1219511992Interstitial nephritis26322N1319711992CGN26022B. Matched control patients who had a renal transplantationNo\#:Born yearHD startDiagnosisFollow up MFollow up YDeath YCoDCancer1419251984CVD160131997CancerY1519161984Heredetary nephropaty139121996Sepsis1619621985Glomerulonephritis34329Y1719421987CVD7261993CVD1819651990Glomerulonephritis284241919521999Glomerulonephritis178152019732011Interstitial nephritis292N^a^Second transplant in 2003, *M*: months, *Y*: year, PCK:polycystic kidney disease, Crescentic *GN*: crescentic glomerulonephritis, *IgAN*: IgA nephritis, *CGN*: Chronic glomerulonephritis, *CoD*: cause of death, *CVD*: cardiovascular diseaseThe cohort was matched based on age, sex and A. initiation of hemodialysis or B. renal transplantation Fig. 3Kaplan Mayer survival curve over the two groups. No statistical differences were seen between the study group (intoxicated patients) and the control group over time

Comparisons between study and control populations {#Sec14}
-------------------------------------------------

Of the 21 patients with ESRD in the study group, 20 were matched; 7 in dialysis and 13 that were transplanted. Cancer was not more frequent in the study group compared to control group. There were 3 cases of cancer in the study population of 21 patients (14%), of which all 3 were transplanted. In the control group 3 out of 20 (15%) were diagnosed with cancer, two of which were transplanted and one which remained in dialysis. In total, 4 patients of 21 with ESRD died in the study group compared to 6 in the control group, see Fig. [3](#Fig3){ref-type="fig"}. There was no statistical difference between survivals in the study group compared to the case control group.

Discussion {#Sec15}
==========

The present study was done to reveal if patients that accidentally ingested deadly webcap (Cortinarius rubellus) suffered from long-term increases in morbidity or mortality. Indeed, 75% of the 28 patients developed CKD5, and 70% of them were transplanted. However, we did not find evidence of any other damage apart from the severe kidney injury. It should be noted that this is still a small patient group and of 39 cases we were only able to investigate 28 cases. Possible confounders could be the limited size of the study or that bias was introduced by co-morbidities or other medication. However, we do not anticipate that this has affected the outcome of the study.

The follow up period after the accidental intake of poisonous webcap is quite long, 16.9 years, with a range of up to 34.3 years. As expected, the long-term survival was excellent after transplantation as reflected by the current follow up period of 19.0 ± 2.5 years for the 14 patients in that group. The result is in accordance with previous reports over shorter periods of follow up \[[@CR17], [@CR22]\]. Regarding dialysis, it is well known that the mortality is high for all age groups \[[@CR23]\]. Naturally, the survival on dialysis will depend, not only on the dialysis practice, but also on the underlying disease and on comorbidities \[[@CR23]--[@CR25]\]. The outcome was quite good for the study population on dialysis, which so far has been followed for 12.4 ± 3.4 years. Some patients have died over the three and a half decades of follow up. However, the patients on dialysis died after more than 12 years of treatment with haemodialysis at a mean age of 68. A similar picture was found in the case control population with follow up periods for transplanted patients of 15.2 ± 2.8 years and of patients on dialysis for 14.4 ± 3.5 years. In the case control population there were three deaths in each of the two ESRD groups, with transplanted patients being 66 years at the time of death, and patients on dialysis being 68. We found no evidence of increased risk for malignancy, endocrinological disorders or other morbidity in the study population.

Conclusion {#Sec16}
==========

We conclude that the long-term outcome is equally good for patients that have lost their renal function due to accidental intake of deadly webcap compared to other reasons for the uraemia. This was true both for transplanted patients and patients treated with dialysis.
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:   Alanine amino transferase
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:   Alkaline phosphatase
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:   Aspartate amino transferase

ATN

:   Acute tubular necrosis

CKD5

:   Chronic kidney disease stage 5

ESRD

:   End stage renal disease

SEM

:   Standard error of the mean
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